GGrantIndex
Sort

39,280 grants matching leukemia

Tumor Microenvironment in Cancer Progression

$1,116,420
Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Molecular Basis for the Pathogenesis of Murine Retroviruses

$1,115,988
Sandra K Ruscetti · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Apoptosis-Based Cancer Drug Discovery

$1,115,725
John C Reed · Sanford Burnham Prebys Medical Discovery Institute · U19 · FY2009 · CA

Cancer and Leukemia Group B Human Specimen Repositories

$1,114,720
Richard L Schilsky · University Of Chicago · U24 · FY2008 · CA

Integrase

$1,113,302
Stephen H Hughes · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Cancer and Leukemia Group B Human Specimen Repositories

$1,113,115
University Of Chicago · U24 · FY2005 · CA

Decoding innate immune signaling in normal and myelodysplastic hematopoiesis

$1,113,000
Daniel Starczynowski · Cincinnati Childrens Hosp Med Ctr · R35 · FY2023 · HL

Apoptosis-Based Cancer Drug Discovery

$1,112,625
John C Reed · Sanford Burnham Prebys Medical Discovery Institute · U19 · FY2008 · CA

Telomere Diseases

$1,112,403
Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL

Immunology And Pathology Of Acute and Chronic Murine Leukemia Virus Infections

$1,110,653
Kim Hasenkrug · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Use of Bacteriophages to Prevent, Diagnose, and Treat Diseases

$1,110,488
Sankar Adhya · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Improved Chimeric Antigen Receptor Therapies B-cell Malignancies

$1,110,078
James Kochenderfer · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

$1,109,810
Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2021 · CA

Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia

$1,109,637
Jeffrey Wallace Tyner · Oregon Health & Science University · U01 · FY2024 · CA

NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

$1,109,082
Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2022 · CA

Clinical Trials with Immunotoxins

$1,108,096
Ira Pastan · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Host Defense Regulation and Viral Oncogenesis

$1,107,550
Glen N. Barber · University Of Miami School Of Medicine · P01 · FY2011 · CA

Eliminating Interference from Autofluorescence in Flow Cytometry

$1,107,310
Giacomo Vacca · Kinetic River Corporation · R44 · FY2023 · GM

Clinical and translational studies of RUNX1 and FPDMM

$1,106,669
Paul Liu · National Human Genome Research Institute · ZIA · FY2021 · HG

Mechanistic and translational studies of CBF leukemia

$1,106,669
Paul Liu · National Human Genome Research Institute · ZIA · FY2021 · HG

NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

$1,106,459
Harold John Burstein · Dana-Farber Cancer Inst · UG1 · FY2023 · CA

PATHOGENESIS OF PERSISTENT VIRAL INJURY TO THE CNS

$1,106,398
University Of Pennsylvania · P01 · FY2002 · NS

ONCOGENES IN CANCER ETIOLOGY AND PROGRESSION

$1,106,271
Thomas Jefferson University · P01 · FY2000 · CA

Metabolic regulation of T cell effector function and anti-tumor immunotherapy

$1,105,926
Naomi Taylor · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

MOUSE MODELS OF MYELOID LEUKEMIA

$1,105,106
University Of California San Francisco · U01 · FY2003 · CA